1. Pioneering cord blood transplantation in relapsed/refractory HIV-related lymphoma: a case study with concurrent intramuscular antiretroviral therapy.
- Author
-
Yokota T, Kurosawa S, Yoshimura Y, Bingo M, Yamaguchi T, Takada Y, So Y, Miyata N, Nakayama H, Sakurai A, Sato K, Ito C, Aisa Y, and Nakazato T
- Subjects
- Humans, Male, Adult, Lymphoma, AIDS-Related drug therapy, Lymphoma, AIDS-Related therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Injections, Intramuscular, Prednisone therapeutic use, Prednisone administration & dosage, Doxorubicin therapeutic use, Doxorubicin administration & dosage, Vincristine therapeutic use, Vincristine administration & dosage, Cyclophosphamide therapeutic use, Cyclophosphamide administration & dosage, Rituximab therapeutic use, Rituximab administration & dosage, Anti-HIV Agents therapeutic use, Anti-HIV Agents administration & dosage, Anti-Retroviral Agents therapeutic use, Anti-Retroviral Agents administration & dosage, Cord Blood Stem Cell Transplantation adverse effects, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse therapy, HIV Infections drug therapy, HIV Infections complications
- Abstract
A 44-year-old HIV-positive man diagnosed with diffuse large B-cell lymphoma in 2021 achieved complete remission with six cycles of R-CHOP therapy but had a relapse in November 2022. ESHAP therapy failed to induce remission, leading to complete remission with four cycles of Pola-BR therapy. Post-failure of autologous stem cell harvest, cord blood transplantation (CBT) was performed in June 2023. Notably, this case used recently approved intramuscular antiretroviral therapy (ART) with cabotegravir and rilpivirine, addressing gastrointestinal complications during CBT. This innovative use of intramuscular ART in the treatment of malignancy represents a first in the field, offering a pioneering approach to HIV-related lymphoma., Competing Interests: Declarations of competing interest None., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF